Routine testing is needed to locate patients who may not benefit from clopidogrel

Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.

May 14, 2026 - 01:00
 0  2
Routine testing is needed to locate patients who may not benefit from clopidogrel
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow